

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Afterpay Touch Group Limited	APT.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Manager in the August 2018 placement of Afterpay Touch Group Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the October 2016 placement of Afterpay Holdings Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Axiom Mining Limited	AVQ.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the August 2016 raising for Axiom Mining Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Bluglass Limited	BLG.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the May 2018 placement for Bluglass Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p> <p>This report was prepared solely by Wilsons Advisory and Stockbroking Limited. ASX did not prepare any part of the report and has not contributed in any way to its content. The role of ASX in relation to the preparation of the research reports is limited to funding their preparation, by Wilsons Advisory and Stockbroking Limited, in accordance with the ASX Equity Research Scheme. ASX does not provide financial product advice. The views expressed in this research report may not necessarily reflect the views of ASX. To the maximum extent permitted by law, no representation, warranty or undertaking, express or implied, is made and no responsibility or liability is accepted by ASX as to the adequacy, accuracy, completeness or reasonableness of the research reports.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Collins Foods Limited	CKF.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the July 2017 Accelerated Non-Renounceable Entitlement Offer of Collins Foods Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited acted as Joint Lead Manager and Underwriter in the March 2017 placement of Collins Foods Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
ELMO Software Limited	ELO.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager to the March 2018 Placement of ELMO Software Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter to the June 2017 IPO of ELMO Software Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
EML Payments Limited	EML.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the May 2016 placement of EML Payments Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Mastermyne Group Limited	MYE.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the September 2017 placement of Mastermyne Group Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Melbourne IT Limited	MLB.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the May 2017 Accelerated Non-Renounceable Entitlement Offer for Melbourne IT limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Micro-X Limited	MX1.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Sole Lead Manager in the April 2017 placement and Non-Renounceable Entitlement Offer for Micro-X Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Noni B Limited	NBL.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter in the May 2018 placement and entitlement offer of Noni B Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p> <p>Wilsons Advisory and Stockbroking Limited has been appointed by Noni B Limited (NBL.ASX) to act as its broker for the on-market buy-back of NBL.ASX ordinary shares.</p> <p>This report was prepared solely by Wilsons Advisory and Stockbroking Limited. ASX did not prepare any part of the report and has not contributed in any way to its content. The role of ASX in relation to the preparation of the research reports is limited to funding their preparation, by Wilsons Advisory and Stockbroking Limited, in accordance with the ASX Equity Research Scheme. ASX does not provide financial product advice. The views expressed in this research report may not necessarily reflect the views of ASX. To the maximum extent permitted by law, no representation, warranty or undertaking, express or implied, is made and no responsibility or liability is accepted by ASX as to the adequacy, accuracy, completeness or reasonableness of the research reports.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
National Veterinary Care Ltd	NVL.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the September 2018 placement of National Veterinary Care Ltd securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Opthea Limited	OPT.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Sole Lead Manager in the April 2017 placement of Opthea Limited securities for which it received fees or will receive fees for acting in this capacity. Post the raising, Wilsons Corporate Finance Limited held a position in OPT. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Oncosil Medical Ltd	OSL.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the April 2018 placement and Share Purchase Plan of Oncosil Medical Ltd securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Pinnacle Investment Management Group Limited	PNI.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the July 2018 placement of Pinnacle Investment Management Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the February 2017 placement of Pinnacle Investment Management Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Retail Food Group Limited	RFG.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager for the October 2017 DRP Shortfall Placement of Retail Food Group Limited securities and earned fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager for the September 2016 DRP Shortfall Placement of Retail Food Group Limited securities and earned fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Rural Funds Group	RFF.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager for the July 2018 Entitlement Offer of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Lead Manager and Underwriter in the June 2017 Entitlement Offer of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited acted as Co-Lead Manager in the July 2016 placement of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Ruralco Holdings Limited	RHL.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the February 2017 placement of Ruralco Holdings Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Silver Chef Limited	SIV.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager for the April 2017 Entitlement Offer of Silver Chef Limited securities and earned fees for acting in this capacity. Wilsons Corporate Finance Limited acted as Joint Lead Manager for the September 2016 DRP Shortfall Placement of Silver Chef Limited securities and earned fees for acting in this capacity. Wilsons Corporate Finance Limited acted as Joint Lead Manager and Underwriter for the April 2016 non-renounceable entitlement offer of Silver Chef Limited securities and earned fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
SomnoMed Limited	SOM.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the February 2018 accelerated pro-rata non-renounceable entitlement offer of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited acted as Lead Manager in the May 2016 placement of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Spheria Emerging Companies Limited	SEC.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Arranger & Joint Lead Manager in the December 2017 IPO of Spheria Emerging Companies Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Telix Pharmaceuticals Limited	TLX.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Joint Underwriter to the Telix Pharmaceuticals Limited November 2017 IPO for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Think Childcare Limited	TNK.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the March 2018 placement of Think Childcare Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
TZ Limited	TZL.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the June 2016 TZ Limited raising for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
VGI Partners Global Investments Limited	VG1.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the September 2017 IPO of VGI Partners Global Investments Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Zenitas Healthcare Limited	ZNT.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Joint Underwriter the November 2017 placement and Accelerated Non-Renounceable Entitlement Offer of Zenitas Healthcare Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the January 2017 IPO of Zenitas Healthcare Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>